Pharvaris got an analyst upgrade after doctors backed its prevention results and saw promise in pills for both uses. FDA reviews are pending, two liver-enzyme cases were reported, and rivals may limit adoption, but the doctor feedback supports a favorable reading.
Offering pills for both preventing attacks and treating them as they happen could help Pharvaris stand apart. Doctors said its prevention results resembled injectable treatments, and they were not worried about 2 liver-enzyme cases. The U.S. and European reviews are still open, and existing options may limit switching. Still, doctor feedback and the chance to offer both uses support a favorable reading.
BioCryst’s Orladeyo is named as a competing treatment, but the report says switching from it may be limited. It gives no new sales or trial result for BioCryst, so this story does not change its outlook.
Follow Pharvaris N.V. (PHVS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PHVS